Clinical trial · no report yet · Phase 3
NCT05374512
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
- NCT05374512 ↗
- Active not recruiting
- AstraZeneca
- 204 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 100 | |
| YouTube | 61 | |
| Podcasts | 38 | |
| X videos | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd; Paclitaxel; Nab-paclitaxel; Carboplatin; Capecitabine; Eribulin mesylate
- Arms
- Dato-DXd · Experimental
- Investigator's Choice of Chemotherapy (ICC) · Active comparator
- Enrollment
- 644
- Primary outcomes
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- May 16, 2022
- Primary completion
- Aug 25, 2025
- Results posted
- No
- Registry record
- NCT05374512 · updated May 15, 2026
Publications
linked from the registry- Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortes J. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1. PubMed 37526149